Over the last two decades this grant has supported studies showing that the then current therapy for insect allergy, whole body extracts, was not effective but that venom immunotherapy was effective. Venom immunotherapy became accepted in the United States (US) and worldwide. In the US, all adult patients with a history of anaphylaxis on insect sting and a positive venom skin test are treated. Recently, investigators in Holland found that if they sting challenge history positive, skin test positive patients, more than 70 percent have no reaction and, they contend, need no therapy. US studies found fewer non-reactors on re-sting. Neither the US nor the Dutch investigators have developed diagnostic parameters to predict which patients will or will not react on stings. The current application is based on the hypothesis that the Dutch study is, in part, correct and that it is unnecessary to treat as many patients as we do now. The investigators will repeat their work and address a flaw in that study - whether a single sting predicts the reaction to subsequent stings. It is known that in the early years of immunotherapy, IgG anti-venom antibodies correlate with clinical protection. It is hypothesized that this is an association, but not a causal one, and that clinical protection results from some other aspect of immunization. Using Fel d 1 peptides to immunize cat allergic individuals leads to a lesser immediate allergic response on exposure to cats. The investigators will immunize patients with peptides from antigen 5. Standard immunotherapy with venom leads to significant side-effects: approximately 50 percent of those treated have reactions ranging from a large local response to systemic anaphylaxis. Peptide immunotherapy does not cause immediate reactions, but in about 50 percent of patients, there is a late """"""""anaphylactic-like"""""""" response, significantly milder in severity than the reactions to the allergen. The investigators hypothesize that these reactions are due to a HRF-like cytokine or one with direct anaphylactogenic properties. They have developed a protocol to ascertain the nature of this response. Finally, the major goal of these studies is to use the stings of more than 200 patients to develop parameters that predict which individuals will have a reaction to a sting. While this has not been accomplished before, this was due to stinging few unprotected individuals and the measurement of a limited number of parameters. It is now planned to study not only immunoglobulin levels but inflammatory cell activation, cytokine production, blood and urine histamine levels, and plasma tryptase and fibrinogen levels.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI008270-31
Application #
2671604
Study Section
Immunological Sciences Study Section (IMS)
Project Start
1976-04-01
Project End
2001-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
31
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Golden, David B K (2010) Long-term outcome after venom immunotherapy. Curr Opin Allergy Clin Immunol 10:337-41
Golden, David B K; Kelly, Denise; Hamilton, Robert G et al. (2009) Dialyzed venom skin tests for identifying yellow jacket-allergic patients not detected using standard venom. Ann Allergy Asthma Immunol 102:47-50
Golden, David B K; Kelly, Denise; Hamilton, Robert G et al. (2009) Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 123:1371-5
Golden, David B K (2007) Insect sting anaphylaxis. Immunol Allergy Clin North Am 27:261-72, vii
Golden, David Bk (2007) What is anaphylaxis? Curr Opin Allergy Clin Immunol 7:331-6
Golden, David B K (2006) Insect sting allergy and venom immunotherapy. Ann Allergy Asthma Immunol 96:S16-21
Cruz, Alvaro A; Naclerio, Robert M; Proud, David et al. (2006) Epithelial shedding is associated with nasal reactions to cold, dry air. J Allergy Clin Immunol 117:1351-8
Wagenmann, M; Baroody, F M; Kagey-Sobotka, A et al. (1994) The effect of terfenadine on unilateral nasal challenge with allergen. J Allergy Clin Immunol 93:594-605
Guo, C B; Liu, M C; Galli, S J et al. (1994) Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. Am J Respir Cell Mol Biol 10:384-90
Essayan, D M; Kagey-Sobotka, A; Lichtenstein, L M (1994) Nearly fatal anaphylaxis following an insect sting. Ann Allergy 73:297-300

Showing the most recent 10 out of 88 publications